Eloxx Pharmaceuticals (ELOX) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($61.3 million vs $50.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | INMB |
|---|---|---|
| Share price | $15.18 | $1.83 |
| Market cap | $61.27M | $50.79M |
| 1-day change | +2.02% | -1.61% |
| YTD return | — | +17.31% |
| 1-year return | — | -8.96% |
| 5-year return | — | -90.17% |
| P/E ratio (TTM) | 4.31 | — |
| EPS (TTM) | $3.52 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $2.60 |
| 52-week low | $8.20 | $1.09 |
| Distance from 52-week high | -35.13% | -29.62% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +151.98% | +282.51% |
| Average volume | 46.44K | 416.29K |
| Shares outstanding | 4.04M | 27.75M |
| Employees | 10 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Healthcare · Biotechnology · 10 employees
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Healthcare · Biotechnology · 21 employees
ELOX vs INMB FAQ
Which is bigger, Eloxx Pharmaceuticals or INmune Bio?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $61.27M compared with $50.79M for INmune Bio (INMB).
Are Eloxx Pharmaceuticals and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.